SCHEMBL13102404

SCHEMBL13102404

CCc1nc2c(F)cccc2c(=O)n1NC(=O)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.49
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
LMNA P02545 3/20 0.48
HTT P42858 2/20 0.48
RXFP1 Q9HBX9 1/20 0.46
HDAC6 Q9UBN7 2/20 0.45
RAB9A P51151 1/20 0.45
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
KDM4E B2RXH2 2/20 0.43
USP2 O75604 2/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
KCNH2 Q12809 1/20 0.41
HDAC11 Q96DB2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102405 0.92 ALDH1A1 (0.45) NPSR1ALDH1A1KMT2AMEN1LMNA
SCHEMBL13102496 0.90 CASP3 (0.40) NPSR1ALDH1A1KMT2AMEN1LMNA
SCHEMBL13101685 0.89 NPSR1 (0.51) NPSR1ALDH1A1KMT2AMEN1LMNA
SCHEMBL13101732 0.89 LMNA (0.44) NPSR1ALDH1A1KMT2AMEN1LMNA
SCHEMBL13101706 0.88 ALDH1A1 (0.44) NPSR1ALDH1A1KMT2AMEN1LMNA
SCHEMBL13101950 0.88 ALDH1A1 (0.52) NPSR1ALDH1A1KMT2AMEN1LMNA
SCHEMBL3061075 0.87 NPSR1 (0.48) NPSR1ALDH1A1KMT2AMEN1LMNA
SCHEMBL13101994 0.87 KMT2A (0.47) NPSR1ALDH1A1KMT2AMEN1LMNA
SCHEMBL13101713 0.87 KDM4E (0.50) KMT2AMEN1LMNARAB9AKDM4E
SCHEMBL3070912 0.87 CYP3A4 (0.52) NPSR1ALDH1A1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329713-B2 Fused ring heterocycles as potassium channel modulators ICAGEN INC. (US) 2012-12-11 US disclosed
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273784-A1 FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS KCNK17, KCNJ2, KCNJ1 NPSR1 1871/4885ALDH1A1 2354/4885KMT2A 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.